Skip to main content
OpenTrials

Clinical trial condition

Infections, Papillomavirus

Explore clinical trials studying Infections, Papillomavirus. Study availability and eligibility vary by location and protocol.

61 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Infections, Papillomavirus trial results

Completed

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

NCT00250276

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +12 more
Locations
  • GSK Investigational Site Hvidovre, Denmark
  • GSK Investigational Site Kaunas, Lithuania
  • GSK Investigational Site Klaipėda, Lithuania
  • GSK Investigational Site Vilnius, Lithuania
View Trial Details
Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

NCT00231413

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site Golden, Colorado, United States
  • GSK Investigational Site Kingston, Rhode Island, United States
  • GSK Investigational Site Salt Lake City, Utah, United States
View Trial Details
Completed

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

NCT00196937

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Munich, Bavaria, Germany
  • GSK Investigational Site Würzburg, Bavaria, Germany
  • GSK Investigational Site Berlin, Germany
  • GSK Investigational Site Bydgoszcz, Poland
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Dax, France
  • GSK Investigational Site Draguignan, France
  • GSK Investigational Site Essey-lès-Nancy, France
  • GSK Investigational Site Le Havre, France
View all 21 locations
View Trial Details
Completed

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

NCT00534638

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site Kotka, Finland
  • GSK Investigational Site Kuopio, Finland
  • GSK Investigational Site Lahti, Finland
  • GSK Investigational Site Rauma, Finland
View Trial Details
Completed

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

NCT01249365

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Parkville, Victoria, Australia
  • GSK Investigational Site Perth, Western Australia, Australia
  • GSK Investigational Site Almada, Portugal
  • GSK Investigational Site Coimbra, Portugal
View all 15 locations
View Trial Details
Completed

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site Iowa City, Iowa, United States
  • GSK Investigational Site Wichita, Kansas, United States
  • GSK Investigational Site Wenatchee, Washington, United States
  • GSK Investigational Site Edmonton, Alberta, Canada
View all 20 locations
View Trial Details
Completed

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

NCT00937950

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Miami, Florida, United States
  • GSK Investigational Site Honolulu, Hawaii, United States
  • GSK Investigational Site Iowa City, Iowa, United States
View all 83 locations
View Trial Details
Completed

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

NCT01190189

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Aurora, Colorado, United States
  • GSK Investigational Site Golden, Colorado, United States
  • GSK Investigational Site Coral Gables, Florida, United States
  • GSK Investigational Site Miami, Florida, United States
View all 28 locations
View Trial Details

Related conditions